CVC Capital Partners said Oct. 10 that Anish Mehta will be appointed CEO of the international women’s health assets portfolio, which the firm agreed to buy from Teva Pharmaceutical Industries in September. Mehta will join from Allergan Plc where he was Head of international business development.
CVC Capital Partners (“CVC”) today announced that former Allergan executive Anish Mehta will be appointed as CEO of the international women’s health assets portfolio which CVC Fund VI agreed to acquire from Teva Pharmaceutical Industries Ltd (“Teva”) on 17th September 2017, subject to receipt of regulatory approvals.
Anish Mehta will join from Allergan Plc, where he was Head of International Business Development, leading a team responsible for corporate development and licensing activity in support of the international business. While there, he led the $40.5 billion divestment of the Actavis Global Generics business to Teva. Prior to this, Anish had responsibility for the European and Middle East businesses for Actavis, where he managed a multi-country portfolio of pharmaceutical products to deliver revenue growth, margin expansion and organisational redesign.
Anish Mehta said: “I am honoured to have this opportunity to partner with CVC and the existing team to lead this exciting new business. The combination of high quality products and a talented team creates a unique opportunity for us to build a leading, global speciality pharmaceutical business dedicated to women’s health”.
Cathrin Petty, Partner and Head of European Healthcare at CVC, added: “Anish is a well-established industry veteran, having spent over 20 years in the global healthcare space. His deep experience in M&A, complex carve outs and building businesses will be invaluable to us as we look to scale this business. I am really delighted that Anish has come on board and I look forward to working closely with him in the future.”